pro 2023 v. r2.0 Search Results


pro 2023 v. r2.0  (treeage software)
90
treeage software pro 2023 v. r2.0
Pro 2023 V. R2.0, supplied by treeage software, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+2023+v%2E+r2%2E0/pro+2023+r2/pmc11348610-60-18-19
Average 90 stars, based on 1 article reviews
pro 2023 v. r2.0 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
decision tree software treeage pro 2023 v. r2.0  (treeage software)
90
treeage software decision tree software treeage pro 2023 v. r2.0
Decision Tree Software Treeage Pro 2023 V. R2.0, supplied by treeage software, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+2023+v%2E+r2%2E0/pro+2011+software/pmc11348610-60-13-19
Average 90 stars, based on 1 article reviews
decision tree software treeage pro 2023 v. r2.0 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
decision tree model  (treeage software)
90
treeage software decision tree model
Decision Tree Model, supplied by treeage software, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+2023+v%2E+r2%2E0/decision+tree+model/pmc11475082-127-3-9
Average 90 stars, based on 1 article reviews
decision tree model - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
treeage (2023 r2.0)  (treeage software)
90
treeage software treeage (2023 r2.0)
A schematic of the model structure. Diagnosed <t>ocular</t> <t>hypertension</t> <t>(OHT)</t> patients with intraocular pressure (IOP) of ≥24 mm Hg entered the model with a set of predefined individual characteristics related to their risk of conversion to glaucoma. An initial decision on treatment was made by a secondary-care health professional. Patients without treatment were referred for annual check-ups in primary care and can be referred back to secondary care following an unfavourable check-up. Patients who met the initial treatment rule in secondary care were treated with prostaglandin analogues (80% of them) or selective laser trabeculoplasty (20% of them). Treated patients with ‘on target’ IOP (ie, IOP reduced by 20% or more compared with the baseline IOP after treatment) were returned to primary care after one clinical visit for continued monitoring, while the treatment was escalated for ‘off-target’ patients following the treatment sequence. For treated or untreated patients monitored in the primary care settings, an observed conversion to glaucoma would trigger a referral to secondary care, and an immediate eye assessment was assumed to be conducted by the hospital ophthalmologists/optometrists to confirm the evidence of glaucoma. Patients with negative glaucoma assessment results would be referred back to primary care, and those with positive assessment results were remained in secondary care. In addition, treated OHT patients monitored in primary care with IOP measures deemed ‘off-target’ would be referred to secondary care. (t) means it’s a time-to-event.
Treeage (2023 R2.0), supplied by treeage software, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+2023+v%2E+r2%2E0/treeage++2023+r2+0+/pmc11367344-116-8-15
Average 90 stars, based on 1 article reviews
treeage (2023 r2.0) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
xsl•fo renderx  (RenderX Inc)
90
RenderX Inc xsl•fo renderx
A schematic of the model structure. Diagnosed <t>ocular</t> <t>hypertension</t> <t>(OHT)</t> patients with intraocular pressure (IOP) of ≥24 mm Hg entered the model with a set of predefined individual characteristics related to their risk of conversion to glaucoma. An initial decision on treatment was made by a secondary-care health professional. Patients without treatment were referred for annual check-ups in primary care and can be referred back to secondary care following an unfavourable check-up. Patients who met the initial treatment rule in secondary care were treated with prostaglandin analogues (80% of them) or selective laser trabeculoplasty (20% of them). Treated patients with ‘on target’ IOP (ie, IOP reduced by 20% or more compared with the baseline IOP after treatment) were returned to primary care after one clinical visit for continued monitoring, while the treatment was escalated for ‘off-target’ patients following the treatment sequence. For treated or untreated patients monitored in the primary care settings, an observed conversion to glaucoma would trigger a referral to secondary care, and an immediate eye assessment was assumed to be conducted by the hospital ophthalmologists/optometrists to confirm the evidence of glaucoma. Patients with negative glaucoma assessment results would be referred back to primary care, and those with positive assessment results were remained in secondary care. In addition, treated OHT patients monitored in primary care with IOP measures deemed ‘off-target’ would be referred to secondary care. (t) means it’s a time-to-event.
Xsl•Fo Renderx, supplied by RenderX Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+2023+v%2E+r2%2E0/xsl%E2%80%A2fo+renderx/pm37561567-327-12-13
Average 90 stars, based on 1 article reviews
xsl•fo renderx - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
a∗pap ψ∗pψp 19 photonics 2023  (Photonics Inc)
86
Photonics Inc a∗pap ψ∗pψp 19 photonics 2023
A schematic of the model structure. Diagnosed <t>ocular</t> <t>hypertension</t> <t>(OHT)</t> patients with intraocular pressure (IOP) of ≥24 mm Hg entered the model with a set of predefined individual characteristics related to their risk of conversion to glaucoma. An initial decision on treatment was made by a secondary-care health professional. Patients without treatment were referred for annual check-ups in primary care and can be referred back to secondary care following an unfavourable check-up. Patients who met the initial treatment rule in secondary care were treated with prostaglandin analogues (80% of them) or selective laser trabeculoplasty (20% of them). Treated patients with ‘on target’ IOP (ie, IOP reduced by 20% or more compared with the baseline IOP after treatment) were returned to primary care after one clinical visit for continued monitoring, while the treatment was escalated for ‘off-target’ patients following the treatment sequence. For treated or untreated patients monitored in the primary care settings, an observed conversion to glaucoma would trigger a referral to secondary care, and an immediate eye assessment was assumed to be conducted by the hospital ophthalmologists/optometrists to confirm the evidence of glaucoma. Patients with negative glaucoma assessment results would be referred back to primary care, and those with positive assessment results were remained in secondary care. In addition, treated OHT patients monitored in primary care with IOP measures deemed ‘off-target’ would be referred to secondary care. (t) means it’s a time-to-event.
A∗Pap ψ∗Pψp 19 Photonics 2023, supplied by Photonics Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+2023+v%2E+r2%2E0/2023+photonics/10__3390_slash_photonics10070857-116-64-66
Average 86 stars, based on 1 article reviews
a∗pap ψ∗pψp 19 photonics 2023 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
tavec rlcp  (TAVEC Inc)
90
TAVEC Inc tavec rlcp
A schematic of the model structure. Diagnosed <t>ocular</t> <t>hypertension</t> <t>(OHT)</t> patients with intraocular pressure (IOP) of ≥24 mm Hg entered the model with a set of predefined individual characteristics related to their risk of conversion to glaucoma. An initial decision on treatment was made by a secondary-care health professional. Patients without treatment were referred for annual check-ups in primary care and can be referred back to secondary care following an unfavourable check-up. Patients who met the initial treatment rule in secondary care were treated with prostaglandin analogues (80% of them) or selective laser trabeculoplasty (20% of them). Treated patients with ‘on target’ IOP (ie, IOP reduced by 20% or more compared with the baseline IOP after treatment) were returned to primary care after one clinical visit for continued monitoring, while the treatment was escalated for ‘off-target’ patients following the treatment sequence. For treated or untreated patients monitored in the primary care settings, an observed conversion to glaucoma would trigger a referral to secondary care, and an immediate eye assessment was assumed to be conducted by the hospital ophthalmologists/optometrists to confirm the evidence of glaucoma. Patients with negative glaucoma assessment results would be referred back to primary care, and those with positive assessment results were remained in secondary care. In addition, treated OHT patients monitored in primary care with IOP measures deemed ‘off-target’ would be referred to secondary care. (t) means it’s a time-to-event.
Tavec Rlcp, supplied by TAVEC Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+2023+v%2E+r2%2E0/tavec+rlcp/10__12659_slash_msm__940409-109-51-52
Average 90 stars, based on 1 article reviews
tavec rlcp - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
tavec discrim  (TAVEC Inc)
90
TAVEC Inc tavec discrim
A schematic of the model structure. Diagnosed <t>ocular</t> <t>hypertension</t> <t>(OHT)</t> patients with intraocular pressure (IOP) of ≥24 mm Hg entered the model with a set of predefined individual characteristics related to their risk of conversion to glaucoma. An initial decision on treatment was made by a secondary-care health professional. Patients without treatment were referred for annual check-ups in primary care and can be referred back to secondary care following an unfavourable check-up. Patients who met the initial treatment rule in secondary care were treated with prostaglandin analogues (80% of them) or selective laser trabeculoplasty (20% of them). Treated patients with ‘on target’ IOP (ie, IOP reduced by 20% or more compared with the baseline IOP after treatment) were returned to primary care after one clinical visit for continued monitoring, while the treatment was escalated for ‘off-target’ patients following the treatment sequence. For treated or untreated patients monitored in the primary care settings, an observed conversion to glaucoma would trigger a referral to secondary care, and an immediate eye assessment was assumed to be conducted by the hospital ophthalmologists/optometrists to confirm the evidence of glaucoma. Patients with negative glaucoma assessment results would be referred back to primary care, and those with positive assessment results were remained in secondary care. In addition, treated OHT patients monitored in primary care with IOP measures deemed ‘off-target’ would be referred to secondary care. (t) means it’s a time-to-event.
Tavec Discrim, supplied by TAVEC Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+2023+v%2E+r2%2E0/tavec+discrim/10__12659_slash_msm__940409-109-37-38
Average 90 stars, based on 1 article reviews
tavec discrim - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
npj precision oncology  (Hormel Health Labs)
90
Hormel Health Labs npj precision oncology
A schematic of the model structure. Diagnosed <t>ocular</t> <t>hypertension</t> <t>(OHT)</t> patients with intraocular pressure (IOP) of ≥24 mm Hg entered the model with a set of predefined individual characteristics related to their risk of conversion to glaucoma. An initial decision on treatment was made by a secondary-care health professional. Patients without treatment were referred for annual check-ups in primary care and can be referred back to secondary care following an unfavourable check-up. Patients who met the initial treatment rule in secondary care were treated with prostaglandin analogues (80% of them) or selective laser trabeculoplasty (20% of them). Treated patients with ‘on target’ IOP (ie, IOP reduced by 20% or more compared with the baseline IOP after treatment) were returned to primary care after one clinical visit for continued monitoring, while the treatment was escalated for ‘off-target’ patients following the treatment sequence. For treated or untreated patients monitored in the primary care settings, an observed conversion to glaucoma would trigger a referral to secondary care, and an immediate eye assessment was assumed to be conducted by the hospital ophthalmologists/optometrists to confirm the evidence of glaucoma. Patients with negative glaucoma assessment results would be referred back to primary care, and those with positive assessment results were remained in secondary care. In addition, treated OHT patients monitored in primary care with IOP measures deemed ‘off-target’ would be referred to secondary care. (t) means it’s a time-to-event.
Npj Precision Oncology, supplied by Hormel Health Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+2023+v%2E+r2%2E0/npj+precision+oncology/pm36964296-102-372-383
Average 90 stars, based on 1 article reviews
npj precision oncology - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
pro (healthcare version  (treeage software)
90
treeage software pro (healthcare version
A schematic of the model structure. Diagnosed <t>ocular</t> <t>hypertension</t> <t>(OHT)</t> patients with intraocular pressure (IOP) of ≥24 mm Hg entered the model with a set of predefined individual characteristics related to their risk of conversion to glaucoma. An initial decision on treatment was made by a secondary-care health professional. Patients without treatment were referred for annual check-ups in primary care and can be referred back to secondary care following an unfavourable check-up. Patients who met the initial treatment rule in secondary care were treated with prostaglandin analogues (80% of them) or selective laser trabeculoplasty (20% of them). Treated patients with ‘on target’ IOP (ie, IOP reduced by 20% or more compared with the baseline IOP after treatment) were returned to primary care after one clinical visit for continued monitoring, while the treatment was escalated for ‘off-target’ patients following the treatment sequence. For treated or untreated patients monitored in the primary care settings, an observed conversion to glaucoma would trigger a referral to secondary care, and an immediate eye assessment was assumed to be conducted by the hospital ophthalmologists/optometrists to confirm the evidence of glaucoma. Patients with negative glaucoma assessment results would be referred back to primary care, and those with positive assessment results were remained in secondary care. In addition, treated OHT patients monitored in primary care with IOP measures deemed ‘off-target’ would be referred to secondary care. (t) means it’s a time-to-event.
Pro (Healthcare Version, supplied by treeage software, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+2023+v%2E+r2%2E0/pro++healthcare+version/pm39800322-37-0-4
Average 90 stars, based on 1 article reviews
pro (healthcare version - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


A schematic of the model structure. Diagnosed ocular hypertension (OHT) patients with intraocular pressure (IOP) of ≥24 mm Hg entered the model with a set of predefined individual characteristics related to their risk of conversion to glaucoma. An initial decision on treatment was made by a secondary-care health professional. Patients without treatment were referred for annual check-ups in primary care and can be referred back to secondary care following an unfavourable check-up. Patients who met the initial treatment rule in secondary care were treated with prostaglandin analogues (80% of them) or selective laser trabeculoplasty (20% of them). Treated patients with ‘on target’ IOP (ie, IOP reduced by 20% or more compared with the baseline IOP after treatment) were returned to primary care after one clinical visit for continued monitoring, while the treatment was escalated for ‘off-target’ patients following the treatment sequence. For treated or untreated patients monitored in the primary care settings, an observed conversion to glaucoma would trigger a referral to secondary care, and an immediate eye assessment was assumed to be conducted by the hospital ophthalmologists/optometrists to confirm the evidence of glaucoma. Patients with negative glaucoma assessment results would be referred back to primary care, and those with positive assessment results were remained in secondary care. In addition, treated OHT patients monitored in primary care with IOP measures deemed ‘off-target’ would be referred to secondary care. (t) means it’s a time-to-event.

Journal: BMJ Open Ophthalmology

Article Title: Cost-effectiveness of monitoring ocular hypertension based on a risk prediction tool

doi: 10.1136/bmjophth-2024-001741

Figure Lengend Snippet: A schematic of the model structure. Diagnosed ocular hypertension (OHT) patients with intraocular pressure (IOP) of ≥24 mm Hg entered the model with a set of predefined individual characteristics related to their risk of conversion to glaucoma. An initial decision on treatment was made by a secondary-care health professional. Patients without treatment were referred for annual check-ups in primary care and can be referred back to secondary care following an unfavourable check-up. Patients who met the initial treatment rule in secondary care were treated with prostaglandin analogues (80% of them) or selective laser trabeculoplasty (20% of them). Treated patients with ‘on target’ IOP (ie, IOP reduced by 20% or more compared with the baseline IOP after treatment) were returned to primary care after one clinical visit for continued monitoring, while the treatment was escalated for ‘off-target’ patients following the treatment sequence. For treated or untreated patients monitored in the primary care settings, an observed conversion to glaucoma would trigger a referral to secondary care, and an immediate eye assessment was assumed to be conducted by the hospital ophthalmologists/optometrists to confirm the evidence of glaucoma. Patients with negative glaucoma assessment results would be referred back to primary care, and those with positive assessment results were remained in secondary care. In addition, treated OHT patients monitored in primary care with IOP measures deemed ‘off-target’ would be referred to secondary care. (t) means it’s a time-to-event.

Article Snippet: A cohort of 50 000 patients with diagnosed OHT were used in the simulation using Treeage (2023 R2.0) for the base-case analysis (the model is available from the authors on request).

Techniques: Analogues, Sequencing